制备一种携紫杉醇和抗人表皮生长因子受体2（HER-2）抗体的高分子造影剂，并考察其体外寻靶能力及体外显像效果。

通过双乳化法及碳二亚胺法制备携紫杉醇和抗HER-2抗体的高分子造影剂，并对其一般性质进行检测，激光共聚焦显微镜观察制备的靶向载药造影剂与SKBR-3乳腺癌细胞的结合能力，并使用高频超声观察其体外显影效果。

载药靶向羧基端乳酸（PLGA）纳米粒平均粒径为（318.07±12.51）nm，表面电位（-2.16±0.31）mV，包封率为（60.00±3.40）%，载药量为（6.00±0.34）%，粒子呈规则球形，大小均一，分散性好。激光共聚焦显微镜观察到抗HER-2抗体和羧基端乳酸-羟基乙酸共聚物（PLGA-COOH）造影剂大量结合，流式细胞术观察到两者的结合率高达（99.59±0.42）%，体外寻靶实验示靶向载药高分子超声造影剂与SBKR-3乳腺癌细胞较强的结合在一起。体外成像实验显示，靶向载药高分子造影剂显像呈细腻均匀点状强回声。

成功制备了携抗HER-2抗体和紫杉醇高分子造影剂，该纳米粒相关性能良好，有较高的载药量及包封率，且与高表达HER-2受体的乳腺癌细胞有较强结合能力，有较好的体外显像效果。

To prepare a high molecular contrast agent carrying paclitaxel and anti human epidermal growth factor receptor-2 (HER-2) antibody, and to investigate the target ability in vitro and its effects on ultrasonography in vitro.

The paclitaxel-loaded and anti HER-2 antibodies polymer contrast agents were prepared by the double emulsion technique and carbodiimide technique, and its general properties were by tested. The combination of drug-loading targeted contrast agent and SKBR-3 breast cancer cells was observed with laser confocal microscope. The effect of imaging in vitro was observed by the high frequency ultrasonography.

The average diameter of drug-loaded targeting carboxyl terminal lactic acid (PLGA) nanoparticle was (318.07±12.51) nm, the surface potential was (-2.16±0.31) mV, the drug encapsulation efficiency was (60.00±3.40)%, the drug loading amounts was (6.00±0.34)%, and the contrast agent was spherical particles with uniform size and good dispersion. Laser confocal microscope found significant combination of anti HER-2 antibody and carboxyl terminal lactic acid/hydroxyacetic acid copolymer (PLGA-COOH) polymer contrast agent. Flow cytometry observed the combination rate was (99.59±0.42)%. Search target experiment in vitro observed drug targeting macromolecular contrast agent and SBKR-3 breast cancer cells had a high binding rate. In vitro imaging experiments showed that drug targeting macromclecular imgaging agent appeared uniform and fine dotted dense hyper-echogenicity.

A kind of her-2-targeted and paclitaxel loaded high molecular contrast agent was successfully prepared. It had good performance, high drug loading amounts and entrapment efficiency. It and SKBR-3 breast cancer cells had a high binding rate. The external imaging was better.